Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
After eating, GLP-1 signals to your brain that youre full
ET Saturday, June 6 DALLAS, JUNE 6, 2026 Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association , an open-access, peer-reviewed journal of the American Heart Association
This discrepancy complicates the interpretation of research results and their applicability to clinical practice
Careful consideration of potential benefits and risks is essential for optimizing treatment outcomes and ensuring patient safety when using GLP-1 RAs in clinical practice
Nausea Nausea is one of the most reported side effects, especially during the first few doses
